Article

Adverse Pregnancy Outcomes Rise with Active PsA/AS Disease and Corticosteroid Use

Active psoriatic arthritis and ankylosing spondylitis can lead to adverse pregnancy outcomes, which grows with corticosteroid use, a study shows.

(©HaveANiceDayPhotoShutterstock.com)

(©HaveANiceDayPhotoShutterstock.com)

Pregnant women with psoriatic arthritis and ankylosing spondylitis with active disease or who are using corticosteroids are at an increased risk for adverse pregnancy outcomes, according to new research.

Published in a recent Arthritis Care & Research issue, the study revealed, while women with psoriasis arthritis and ankylosing spondylitis have overall favorable pregnancy outcomes, preterm birth, preterm labor, and Caesarian deliveries are more common if they have active disease.

“Unfortunately, data is lacking on pregnancy outcomes, often making it difficult for rheumatologists and obstetricians to counsel their patients effectively,” said study author Chelsey Smith, M.D., a rheumatologist affiliated with Cedars-Sinai Medical Center. “The goal of our prospective cohort trial is to add to the very limited amount of robust data on pregnancy outcomes and disease activity in these two chronic inflammatory diseases.”

To determine the effect of these conditions, researchers analyzed pregnancy outcomes on 963 women - 117 with psoriatic arthritis, 129 with ankylosing spondylitis, and 717 in a comparison group. Women in both disease groups experienced more co-morbid conditions, including asthma, diabetes, hypertension, depression, and anxiety.

Based on study results, women with active psoriatic arthritis later in pregnancy were at an increased risk for moderate preterm delivery between 32 and 37 weeks, preterm labor, low amniotic fluid, and Caesarian delivery. However, investigators said, the reasons behind the increased risk for low amniotic fluid and Caesarian delivery remain unclear.

The greatest threat to women with ankylosing spondylitis was a 67-percent increased risk for infant hospitalization in the neonatal intensive care unit. In addition, women with high disease activity were also at an increased risk for Caesarian delivery, although, as with the psoriatic arthritis group, the reason isn’t clear.

And, despite American College of Rheumatology recommendations against it, investigators identified high systemic corticosteroid use among women with ankylosing spondylitis. Study findings revealed use in the second trimester was associated with an increased preterm delivery risk. Due to this risk, researchers suggested considering alternative medications first when clinically appropriate.

Overall, they said, additional investigations are needed to further understand how medication use and different disease measures affect pregnancy outcomes in these two conditions.

 

REFERENCE

Smith C, Bandoli G, Kavanaugh A, Chambers C, Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis.Arthritis Care & Research (2019), doi: 10.1002/acr.23924

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.